Home/News Feed/Novartis rated Hold with 12% downside risk amid near-term product pressure and long-term pipeline growth potential.

$160.81

-$0.29 -0.18%

Novartis rated Hold with 12% downside risk amid near-term product pressure and long-term pipeline growth potential.

Analyst Insights

31 Oct 2026, 11:10 WIB

Seeking Alpha

View Source

Neutral

Novartis rated Hold with 12% downside risk amid near-term product pressure and long-term pipeline growth potential.

Novartis is rated Hold with a 12-month price target of $141.81, suggesting a 12% downside from current levels. The company faces near-term challenges on some products, but its drug development pipeline could support growth over the longer term. Valuation is mixed, with Novartis trading at a discount on forward P/E but a premium on EV/EBITDA compared to peers. Risks remain from patent expirations and uncertainties in clinical and regulatory outcomes for pipeline drugs.

Novartis shares are trading at USD 160.81 on Pluang, slightly down by 0.18% as of Oct 31, 2026 15:21 WIB. The stock shows a dividend yield of 3.04% and a market cap of $294.37 billion at this time.

More News (NVS)

Monte Rosa hits $37.5M milestone as Novartis starts Phase 2 trial for arthritis drug MRT-6160

Monte Rosa Therapeutics announced that Novartis has initiated a second Phase 2 clinical trial for MRT-6160 (DDY391), targeting moderate to severe psoriatic arthritis. This follows a prior Phase 2 trial in Sjögren's disease and triggers a $37.5 millio...

Company Fundamentals

Bullish

3 days ago

Novartis rated Hold with 12% downside risk amid near-term product pressure and long-term pipeline growth potential.

More News (NVS)

Monte Rosa hits $37.5M milestone as Novartis starts Phase 2 trial for arthritis drug MRT-6160

Invest & Trade with#1 Award-Winning Investment Super App

Invest & Trade with
#1 Award-Winning Investment Super App